Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer

• Published in: Journal for immunotherapy of cancer Vol. 12; no. 2; p. e008215
• Main Authors: Ravi, Praful, Freeman, Dory, Thomas, Jonathan, Ravi, Arvind, Mantia, Charlene, McGregor, Bradley A, Berchuck, Jacob E, Epstein, Ilana, Budde, Petra, Ahangarian Abhari, Behnaz, Rupieper, Elena, Gajewski, Jana, Schubert, Ann-Sophie, Kilian, Annika L, Bräutigam, Manuel, Zucht, Hans-Dieter, Sonpavde, Guru
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 02-02-2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Aged; Antigens; Antigens, Neoplasm; Autoantibodies; Autoimmunity; Bladder cancer; Blood & organ donations; Cancer therapies; Carcinoma, Transitional Cell; Chemotherapy; Humans; Immune system; Immunity, Humoral; Immunoassay; Immunotherapy; Immunotherapy Biomarkers; Jumonji Domain-Containing Histone Demethylases; Male; Medical prognosis; Membrane Proteins; Patients; Tumors; Urinary Bladder Neoplasms; United States > US; Autoimmunity; Urinary Bladder Neoplasms; Immunity, Humoral; Immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2023-008215

BackgroundComprehensive profiling of autoantibodies (AAbs) in metastatic urothelial cancer (mUC) has not been performed to date. This may aid in diagnosis of UC, uncover novel therapeutic targets in this disease as well as identify associations between AAbs and response and toxicity to systemic therapies.MethodsWe used serum from patients with mUC collected prior to and after systemic therapy (immune checkpoint inhibitor (ICI) or platinum-based chemotherapy (PBC)) at Dana-Farber Cancer Institute. 38 age-matched and sex-matched healthy controls (HCs) from healthy blood donors were also evaluated. The SeroTag immuno-oncology discovery array (Oncimmune) was used, with quantification of the AAb reactivity toward 1132 antigens. Bound AAbs were detected using an anti-immunoglobulin G-specific detection antibody conjugated to the fluorescent reporter dye phycoerythrin. The AAb reactivity was reported as the median fluorescence intensity for each color and sample using a Luminex FlexMAP3D analyzer. Clinical outcomes of interest included radiographic response and development of immune-related adverse events (irAEs). Significance analysis of microarray was used to compare mUC versus HC and radiographic response. Associations with irAE were evaluated using a logistic regression model. P<0.05 was considered statistically significant.Results66 patients were included with a median age of 68 years; 54 patients (82%) received ICI and 12 patients (18%) received PBC. Compared with HCs, AAbs against the cancer/testis antigens (CTAG1B, CTAG2, MAGEB18), HSPA1A, TP53, KRAS, and FGFR3 were significantly elevated in patients with mUC. AAbs against BRCA2, TP53, and CTNBB1 were associated with response, and those against BICD2 and UACA were associated with resistance to ICI therapy. AAbs against MITF, CDH3, and KDM4A were associated with development of irAEs in patient who received an ICI. A higher variance in pre-to-post treatment fold change in AAb levels was seen in patients treated with ICI versus PBC and was associated with response to ICI.ConclusionsThis is the first report of comprehensive AAb profiling of patients with mUC and identified key AAbs that were elevated in patients with mUC versus HCs as well as AAbs associated with therapeutic response to ICI. These findings are hypothesis generating and further mechanistic studies evaluating humoral immunity in UC are required.